Ovid Therapeutics Financials
OVID Stock | USD 1.05 0.01 0.94% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 17.25 | 9.5516 |
|
|
The essential information of the day-to-day investment outlook for Ovid Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Ovid Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Ovid Therapeutics.
Net Income |
|
Ovid | Select Account or Indicator |
Understanding current and past Ovid Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Ovid Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Ovid Therapeutics' assets may result in an increase in income on the income statement.
Please note, the presentation of Ovid Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ovid Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ovid Therapeutics' management manipulating its earnings.
Ovid Therapeutics Stock Summary
Ovid Therapeutics competes with CytomX Therapeutics, Spero Therapeutics, Instil Bio, NextCure, and Assembly Biosciences. Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company was incorporated in 2014 and is headquartered in New York, New York. Ovid Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 44 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US6904691010 |
CUSIP | 690469101 |
Location | New York; U.S.A |
Business Address | 41 Ninth Avenue, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.ovidrx.com |
Phone | 646 661 7661 |
Currency | USD - US Dollar |
Ovid Therapeutics Key Financial Ratios
Return On Equity | -0.37 | ||||
Operating Margin | (76.45) % | ||||
Price To Sales | 119.16 X | ||||
Revenue | 391.69 K | ||||
Gross Profit | 1.5 M |
Ovid Therapeutics Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 80.8M | 75.9M | 194.5M | 155.3M | 144.0M | 100.8M | |
Net Tangible Assets | 69.6M | 43.3M | 179.7M | 132.3M | 152.1M | 81.7M | |
Retained Earnings | (213.2M) | (294.2M) | (171.4M) | (225.5M) | (277.9M) | (264.0M) | |
Accounts Payable | 3.3M | 5.4M | 7.1M | 2.0M | 3.7M | 3.2M | |
Cash | 41.9M | 72.0M | 187.8M | 129.0M | 27.0M | 25.7M | |
Other Assets | 494.9K | (100.0) | 2.0M | 1.9M | 1.0 | 0.95 | |
Total Liab | 10.8M | 32.3M | 14.8M | 23.0M | 56.2M | 59.0M | |
Total Current Assets | 79.8M | 74.8M | 190.5M | 131.4M | 109.6M | 93.1M | |
Intangible Assets | 467.2K | 318.9K | 260.1K | 261.2K | 183.0K | 235.2K | |
Common Stock | 54.7K | 65.7K | 70.4K | 70.5K | 70.7K | 47.4K | |
Other Current Liab | 7.3M | 14.4M | 7.7M | 4.5M | 6.5M | 6.6M | |
Net Debt | (41.9M) | (72.0M) | (187.8M) | (112.5M) | (11.0M) | (11.6M) | |
Other Current Assets | 1.9M | 2.7M | 2.7M | 2.4M | 3.8M | 2.2M | |
Capital Surpluse | 283.1M | 337.8M | 351.0M | 357.8M | 411.4M | 312.6M | |
Net Invested Capital | 70.0M | 43.6M | 179.7M | 132.3M | 87.8M | 99.9M | |
Net Working Capital | 69.3M | 52.8M | 175.7M | 124.4M | 98.1M | 100.3M | |
Capital Stock | 54.7K | 65.7K | 70.4K | 70.5K | 70.7K | 65.4K |
Ovid Therapeutics Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 5.4M | 30.1M | 117.7M | (142.9M) | (17.8M) | (16.9M) | |
Depreciation | 255.0K | 306.8K | 237.1K | 1.4M | 1.6M | 1.7M | |
Capital Expenditures | 244.0K | 390.7K | 189.4K | 1.4M | 137.5K | 130.6K | |
Net Income | (60.5M) | (81.0M) | 122.8M | (54.2M) | (52.3M) | (49.7M) | |
End Period Cash Flow | 41.9M | 72.0M | 189.7M | 46.8M | 27.0M | 25.7M | |
Change To Netincome | 5.2M | 7.3M | 5.1M | 6.6M | 7.5M | 8.9M | |
Investments | (29.8M) | 35.0M | (1.6M) | (85.5M) | 41.8M | 43.9M | |
Free Cash Flow | (51.3M) | (52.0M) | 118.4M | (56.6M) | (45.9M) | (48.2M) | |
Other Non Cash Items | (29.6K) | (199.4K) | 7.3M | (764.9K) | (4.7M) | (4.5M) |
Ovid Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ovid Therapeutics's current stock value. Our valuation model uses many indicators to compare Ovid Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ovid Therapeutics competition to find correlations between indicators driving Ovid Therapeutics's intrinsic value. More Info.Ovid Therapeutics is regarded third in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Ovid Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Ovid Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Ovid Therapeutics Systematic Risk
Ovid Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Ovid Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Ovid Therapeutics correlated with the market. If Beta is less than 0 Ovid Therapeutics generally moves in the opposite direction as compared to the market. If Ovid Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Ovid Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Ovid Therapeutics is generally in the same direction as the market. If Beta > 1 Ovid Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Ovid Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Ovid Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Ovid Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Ovid Therapeutics November 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Ovid Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Ovid Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Ovid Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Ovid Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Ovid Therapeutics's daily price indicators and compare them against related drivers.
Information Ratio | (0.05) | |||
Maximum Drawdown | 19.2 | |||
Value At Risk | (6.25) | |||
Potential Upside | 5.93 |
Complementary Tools for Ovid Stock analysis
When running Ovid Therapeutics' price analysis, check to measure Ovid Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ovid Therapeutics is operating at the current time. Most of Ovid Therapeutics' value examination focuses on studying past and present price action to predict the probability of Ovid Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ovid Therapeutics' price. Additionally, you may evaluate how the addition of Ovid Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |